Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

Kenji Kabashimaa Department of Dermatology, Graduate School of Medicine, Kyoto University, Kyoto, JapanCorrespondence[email protected]

https://orcid.org/0000-0002-0773-0554 View further author information

Takayo Matsumurab Department of Clinical Development, Maruho Co., Ltd., Kyoto, Japan

https://orcid.org/0000-0002-0986-8469 View further author information

Yoshiteru Hayakawac Medical Affairs Department, Maruho Co., Ltd., Osaka, JapanView further author information

Makoto Kawashimad Tokyo Women’s Medical University, Tokyo, Japan

https://orcid.org/0000-0001-6877-9979 View further author information

& for the Nemolizumab-JP01 Study Group

Figures & data

Table 1. Baseline demographic and clinical characteristics in the modified intention-to-treat population, and by responder^a subgroups in the nemolizumab treatment group.

Download CSV Display Table

Figure 1. Subgroup analysis (analysis of covariance) for percent change from baseline at week 16 in pruritus visual analog scale (VAS) and Eczema Area and Severity Index (EASI) responders (nemolizumab treatment group). *Responder was defined as those who achieved an improvement of ≥50% from baseline at week 16 for either VAS or EASI. CI: confidence interval; DLQI: Dermatology Life Quality Index; NRS: numerical rating scale; POEM: Patient-Oriented Eczema Measure; sIGA: static Investigator’s Global Assessment.

Figure 4. Subgroup analysis (analysis of covariance) for percent change from baseline at week 16 in pruritus visual analog scale (VAS) and Eczema Area and Severity Index (EASI) scores (modified intention-to-treat population). CI: confidence interval; DLQI: Dermatology Life Quality Index; ISI: Insomnia Severity Index; LS: least squares; POEM: Patient-Oriented Eczema Measure; SE: standard error; sIGA: static Investigator’s Global Assessment.

Data availability statement

The authors are unable to provide individual patient data as consent for distribution of personal information was not obtained in the clinical trial.

Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

Table 1. Baseline demographic and clinical characteristics in the modified intention-to-treat population, and by responder^a subgroups in the nemolizumab treatment group.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial

Figures & data

Table 1. Baseline demographic and clinical characteristics in the modified intention-to-treat population, and by respondera subgroups in the nemolizumab treatment group.

Data availability statement

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 1. Baseline demographic and clinical characteristics in the modified intention-to-treat population, and by responder^a subgroups in the nemolizumab treatment group.